Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

725
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
725
Cancer Vaccines01:30

Cancer Vaccines

556
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
556
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.9K
Cancer Therapies02:49

Cancer Therapies

8.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Tandem mass spectrometry based study on the dissipation behaviour, dietary risk assessment and decontamination of chlorfenapyr, fenvalerate, and tolfenpyrad residues in broccoli.

Environmental geochemistry and health·2026
Same author

Comparative Evaluation of Analytical Methods for the Determination of Insecticide Residues in Green Chilli (Capsicum annuum L.) Fruits.

Biomedical chromatography : BMC·2026
Same author

Tandem mass spectrometry based study on the dissipation behaviour, dietary risk assessment and decontamination of chlorfenapyr, fenvalerate, and tolfenpyrad residues in broccoli.

Environmental geochemistry and health·2026
Same author

Impact of digital supportive supervision (DiSS) on the extent of maternal and child healthcare service utilisation in India: a sequential mixed-methods quasi-experimental study.

BMJ open·2026
Same author

Residue Analysis, Dissipation Kinetics and Risk Assessment of Tolfenpyrad and Emamectin Benzoate in Cauliflower and Brinjal Using LC/MS and TQ.

Environmental toxicology·2025
Same author

Exploring residue profiles and risk assessment of azoxystrobin and chlorothalonil in peas (Pisum sativum L.).

Environmental geochemistry and health·2025

Related Experiment Video

Updated: Oct 11, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K

Improving cancer immunotherapy by targeting IL-1.

Zhilan Xiao1, Shubhra Singh2, Manisha Singh2

  • 1Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Oncoimmunology
|December 3, 2021
PubMed
Summary

Interleukin-1 (IL-1) drives tumor immune evasion and therapy resistance. Targeting the IL-1 pathway may improve melanoma immunotherapy effectiveness by overcoming this immune suppression.

Keywords:
IL-1Inflammationcancerimmunotherapy

More Related Videos

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

Related Experiment Videos

Last Updated: Oct 11, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Interleukin-1 (IL-1) is an inflammatory cytokine linked to tumor invasiveness and metastasis.
  • Both baseline and therapy-induced IL-1 contribute to immune suppression within the tumor microenvironment.
  • IL-1 promotes resistance to immunotherapy in melanoma models.

Purpose of the Study:

  • To discuss the mechanisms by which IL-1 induces immune suppression and immunotherapy resistance.
  • To explore the potential of targeting the IL-1 pathway to enhance cancer treatment efficacy.

Main Methods:

  • Review of existing literature on IL-1 in cancer immunology.
  • Analysis of IL-1's role in melanoma progression and response to immunotherapy.
  • Discussion of therapeutic strategies targeting the IL-1 pathway.

Main Results:

  • Naturally occurring IL-1 in tumors creates an immunosuppressive microenvironment.
  • IL-1 induced by CD40 agonist immunotherapy also leads to treatment resistance.
  • IL-1 signaling pathways are critical mediators of immune evasion in cancer.

Conclusions:

  • IL-1 is a key factor in tumor-induced immune suppression and resistance to immunotherapy.
  • Targeting the IL-1 pathway represents a promising strategy to improve immunotherapy outcomes in cancer patients.